Hikma Pharmaceuticals Correlations
| HKMPF Stock | USD 24.47 1.91 8.47% |
The current 90-days correlation between Hikma Pharmaceuticals PLC and Titan Machinery is 0.19 (i.e., Average diversification). The correlation of Hikma Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Hikma Pharmaceuticals Correlation With Market
Average diversification
The correlation between Hikma Pharmaceuticals PLC and DJI is 0.11 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Hikma Pharmaceuticals PLC and DJI in the same portfolio, assuming nothing else is changed.
Hikma |
The ability to find closely correlated positions to Hikma Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hikma Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hikma Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hikma Pharmaceuticals PLC to buy it.
Moving together with Hikma Pink Sheet
| 0.86 | MKKGY | Merck KGaA ADR | PairCorr |
| 0.83 | MKGAF | MERCK Kommanditgesells | PairCorr |
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.83 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.73 | HLNCF | Haleon plc | PairCorr |
| 0.66 | TEVA | Teva Pharma Industries | PairCorr |
| 0.84 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | KO | Coca Cola Aggressive Push | PairCorr |
Moving against Hikma Pink Sheet
| 0.86 | PLTR | Palantir Technologies Aggressive Push | PairCorr |
| 0.74 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.58 | GLABF | Gemina Laboratories | PairCorr |
| 0.84 | CVX | Chevron Corp Sell-off Trend | PairCorr |
| 0.74 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
| 0.72 | T | ATT Inc Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.71 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.65 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.62 | HPQ | HP Inc | PairCorr |
| 0.55 | HD | Home Depot | PairCorr |
| 0.52 | XOM | Exxon Mobil Corp Fiscal Year End 7th of February 2025 | PairCorr |
Related Correlations Analysis
| -0.74 | -0.53 | -0.5 | -0.17 | 0.0 | LBNKF | ||
| -0.74 | 0.77 | 0.68 | 0.23 | 0.0 | UVSP | ||
| -0.53 | 0.77 | 0.45 | 0.35 | 0.0 | CMWAY | ||
| -0.5 | 0.68 | 0.45 | 0.21 | 0.0 | TITN | ||
| -0.17 | 0.23 | 0.35 | 0.21 | 0.0 | WNW | ||
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | UPPR | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Hikma Pink Sheet performing well and Hikma Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Hikma Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| LBNKF | 3.57 | (0.94) | 0.00 | 9.34 | 0.00 | 6.67 | 18.77 | |||
| UVSP | 1.49 | (0.05) | 0.05 | 0.10 | 1.57 | 3.37 | 18.49 | |||
| CMWAY | 0.95 | 0.12 | 0.01 | 0.69 | 1.04 | 2.22 | 7.38 | |||
| TITN | 2.24 | (0.18) | 0.02 | 0.06 | 2.69 | 5.83 | 19.53 | |||
| WNW | 2.76 | 0.32 | 0.08 | 0.65 | 2.63 | 7.41 | 29.28 | |||
| UPPR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hikma Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Hikma Pharmaceuticals Corporate Management
| Engineer Darwazah | Ex CEO | Profile | |
| Khalid Nabilsi | Chief Officer | Profile | |
| CPA CFA | Exec MA | Profile | |
| Brian Hoffmann | Pres Generics | Profile | |
| Hussein Arkhagha | General Counsel | Profile |